Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Dr. Falk Pharma GmbH |
---|---|
Information provided by: | Dr. Falk Pharma GmbH |
ClinicalTrials.gov Identifier: | NCT00450086 |
The purpose of this study is to determine whether budesonide or mesalazine is more active in the treatment of collagenous colitis.
Condition | Intervention | Phase |
---|---|---|
Collagenous Colitis |
Drug: Budesonide Drug: Mesalazine Drug: Placebo |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Double-Blind, Double-Dummy, Randomised, Placebo-Controlled, Multi-Centre Phase III Clinical Study on the Efficacy and Tolerability of Budesonide Capsules vs. Mesalazine Granules vs. Placebo for Patients With Collagenous Colitis. |
Estimated Enrollment: | 96 |
Study Start Date: | March 2007 |
Estimated Study Completion Date: | July 2009 |
Estimated Primary Completion Date: | June 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
A: Experimental |
Drug: Budesonide
9 mg per day
|
B: Experimental |
Drug: Mesalazine
3 g per day
|
C: Placebo Comparator |
Drug: Placebo
0 g per day
|
This study will check the reproducibility of the results reported in trials with budesonide in patients with collagenous colitis. Efficacy of mesalazine was never tested in collagenous colitis by placebo-controlled trials. This trial will check the superiority of mesalazine over placebo using the common clinical symptom of collagenous colitis, which is chronic or recurrent non-bloody, watery diarrhea.
Ages Eligible for Study: | 18 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria (main):
Exclusion Criteria:
Contact: Ralf Mohrbacher | ++49 761 1514-0 ext -156 | mohrbacher@drfalkpharma.de |
Germany | |
Medical Department I, University Hospital Carl Gustav Carus, Technical University | Recruiting |
Dresden, Germany, 01307 | |
Contact: Stephan Miehlke, Professor ++49 351 458-0 ext -5645 stephan.miehlke@uniklinikum-dresden.de | |
Contact: Ahmed Madisch, MD ++49 351 458-0 ext -5645 ahmed.madisch@uniklinikum-dresden.de |
Principal Investigator: | Stephan Miehlke, Professor | Medical Department I, University Hospital Carl Gustav Carus, Technical University, Dresden, Germany |
Responsible Party: | ( Dr. Falk Pharma GmbH ) |
Study ID Numbers: | BUC-60/COC, 2006-004159-39 |
Study First Received: | March 20, 2007 |
Last Updated: | January 12, 2009 |
ClinicalTrials.gov Identifier: | NCT00450086 |
Health Authority: | Germany: Federal Institute for Drugs and Medical Devices |
Colitis, Microscopic Digestive System Diseases Mesalamine Gastrointestinal Diseases Colonic Diseases Budesonide |
Collagenous colitis Colitis, Collagenous Intestinal Diseases Gastroenteritis Colitis |
Anti-Inflammatory Agents Respiratory System Agents Physiological Effects of Drugs Hormones, Hormone Substitutes, and Hormone Antagonists Anti-Asthmatic Agents Glucocorticoids Hormones Pharmacologic Actions Sensory System Agents |
Analgesics, Non-Narcotic Autonomic Agents Therapeutic Uses Anti-Inflammatory Agents, Non-Steroidal Analgesics Peripheral Nervous System Agents Antirheumatic Agents Central Nervous System Agents Bronchodilator Agents |